Amyotrophic lateral sclerosis has 1,569 total clinical trials, representing a significantly smaller research investment compared to AD and PD. The limited Phase 3 count (71) reflects the challenge of conducting large-scale trials for this rapidly progressive disease. The high termination rate (103 trials) highlights the need for better therapeutic targets.
Amyotrophic lateral sclerosis has 1,569 total clinical trials, representing a significantly smaller research investment compared to AD and PD. The limited Phase 3 count (71) reflects the challenge of conducting large-scale trials for this rapidly progressive disease. The high termination rate (103 trials) highlights the need for better therapeutic targets.
Key Investment Themes
Genetic Subtypes: Growing stratification based on SOD1, C9orf72, and other genetic markers
Neuroprotection: Emphasis on preserving motor neuron function
Repositioning: Drug repurposing from other neurological conditions
Biomarkers: Critical need for trial enrichment biomarkers
Emerging Investment Areas
With 103 terminated trials, ALS remains one of the most challenging neurodegenerative indications. RNAi-based therapies targeting SOD1 and C9orf72 have shown promise in early trials. Astrocyte modulation represents a novel approach to restore neuronal support. Metabolic interventions targeting energy dysfunction are gaining traction as a complementary strategy.
Priority Research Gaps
Late-Stage Development Bottleneck
Only 4.5% of trials are in Phase 3, indicating a significant gap between early discovery and late-stage clinical development. Investment in clinical trial infrastructure and regulatory engagement could accelerate late-stage programs.
Recommended Priorities
Phase 2→3 Translation: Enhance predictive biomarkers and clinical endpoints
Trial Design Innovation: Adaptive trials and platform protocols
Patient Recruitment: Investment in trial-ready cohorts and registry infrastructure
Therapeutic Target Priorities
Based on trial count analysis, the following mechanism categories represent either well-invested areas or underserved opportunities:
mitochondrial: 696 trials - Well-established
genetic: 117 trials - Well-established
amyloid: 74 trials - Well-established
tau: 37 trials - Growing area
tauro: 37 trials - Growing area
Recent Investment Developments (2024-2025)
Approved Therapies
ALS has seen meaningful therapeutic advances:
Tofersen (Qalsody, Biogen): First FDA-approved ASO for SOD1-ALS (2023), validated genetic targeting
Riluzole: Continued use; AMX0035 (Cyren) showed survival benefit but FDA decision pending
Edaravone (Radicava): Approved 2017, remains standard of care
Key Pipeline Updates (2025)
Rozanolixizumab (UCB): Anti-glycan antibody in Phase 3 for C9orf72-ALS
Ibudilast ( MediciNova): Neuroinflammatory modulator in Phase 2/3
CNM-Au8 (Clene): Catalytic gold nanoparticles in Phase 3 for ALS/PD
TPM-0032 (Transposon): Gene therapy for C9orf72 advancing to Phase 2
Masitinib (AB Science): Tyrosine kinase inhibitor with Phase 3 data expected 2025
Investment Themes
Genetic stratification: SOD1 and C9orf72 targeting drives investment
RNA therapeutics: Multiple ASOs and RNAi programs in development
Neuroprotection: Broad focus on preserving motor neuron function
Astrocyte modulation: Novel approach to restore neuronal support
Recent Deals
Biogen/Longitude: Acquisition of ALS pipeline including tofersen follow-ons
Lily/Prevail: Strategic partnership for gene therapy in genetic forms of ALS
Investment Outlook
Near-Term Opportunities (1-3 Years)
Continued Phase 2/3 readouts expected for leading mechanisms. Focus on biomarker-positive trials for enrichment. Regulatory pathways becoming clearer for disease-modifying therapies.
Medium-Term Opportunities (3-5 Years)
Gene therapies and RNA-targeting modalities expected to expand. Combination therapy trials likely to increase. Patient stratification through genetic and biomarker testing becoming standard.
Long-Term Vision (5-10 Years)
Prevention trials in pre-symptomatic populations. Personalized medicine approaches based on genetic profiles. Disease-modifying therapies potentially becoming standard of care.